Education
About Us
Working with TipRanks
Follow Us
Mind Medicine (DE:MMQ)
FRANKFURT:MMQ
MMQ Stock Chart & Stats
Day’s Range― - ―
52-Week Range€4.65 - €12.03
Previous CloseN/A
Volume187.00
Average Volume (3M)172.00
Market Cap
$428.58M
Enterprise Value€185.59M
Total Cash (Recent Filing)$273.74M
Total Debt (Recent Filing)$21.85M
Price to Earnings (P/E)―
Beta0.90
Next Earnings
May 14, 2025EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.76
Shares Outstanding75,368,360
10 Day Avg. Volume90
30 Day Avg. Volume172
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.75
Forecast
1Y Price Target
€21.33Price Target Upside262.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Bulls Say, Bears Say
Bulls Say
Cash PositionMindMed ended 2024 with $274M in cash which it expects will be sufficient to fund operations into 2027.
Phase 3 TrialsSolid enrollment and maintained Phase 3 data timelines are encouraging.
Regulatory ProgressMindMed announced it has secured alignment with the FDA, including a reduction in required treatment session duration to 8 hours, which strengthens the feasibility of MM120 as a commercial therapy.
Bears Say
Execution RiskMindMed's lead compound, MM120, appears positioned to disrupt the treatment paradigm for generalized anxiety disorder (GAD) and major depressive disorder (MDD), indications with high unmet need in neuropsychiatry.
Market CompetitionThe emerging psychedelics space has clear FDA guidance for regulatory approval, which is a positive signal for Mind Medicine Inc.
---
Options Prices
Currently, No data available
---
Ownership Overview
3.29% Insiders
5.33%
Mutual Funds
23.83% Other Institutional Investors
59.35% Public Companies and
Individual Investors
MMQ FAQ
What was Mind Medicine’s price range in the past 12 months?
Mind Medicine lowest stock price was €4.65 and its highest was €12.03 in the past 12 months.
What is Mind Medicine’s market cap?
Mind Medicine’s market cap is $428.58M.
When is Mind Medicine’s upcoming earnings report date?
Mind Medicine’s upcoming earnings report date is May 14, 2025 which is in 43 days.
How were Mind Medicine’s earnings last quarter?
Mind Medicine released its earnings results on Mar 06, 2025. The company reported -€0.38 earnings per share for the quarter, missing the consensus estimate of -€0.271 by -€0.108.
Is Mind Medicine overvalued?
According to Wall Street analysts Mind Medicine’s price is currently Undervalued.
Does Mind Medicine pay dividends?
Mind Medicine does not currently pay dividends.
What is Mind Medicine’s EPS estimate?
Mind Medicine’s EPS estimate is -0.33.
How many shares outstanding does Mind Medicine have?
Mind Medicine has 75,368,360 shares outstanding.
What happened to Mind Medicine’s price movement after its last earnings report?
Mind Medicine reported an EPS of -€0.38 in its last earnings report, missing expectations of -€0.271. Following the earnings report the stock price went up 1.121%.
Which hedge fund is a major shareholder of Mind Medicine?
Currently, no hedge funds are holding shares in DE:MMQ
---
Mind Medicine Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€21.33 (262.77% Upside)
€21.33 (262.77% Upside)
Blogger Sentiment
Bullish
DE:MMQ Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $17.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.14%
12-Months-Change
Fundamentals
Return on Equity
-68.01%
Trailing 12-Months
Asset Growth
142.61%
Trailing 12-Months
Company Description
Mind Medicine
Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The firm is having an approach towards developing the next generation of psychedelic inspired medicines and therapies.
---
MMQ Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted MindMed's strong financial position and progress towards Phase III trials, while also acknowledging rising R&D expenses and a net loss. The sentiment leans towards positive due to the company's strong cash reserves and clear roadmap for advancing clinical trials.Read More>---
MMQ Stock 12 Month Forecast
Average Price Target
€21.33
▲(262.77% Upside)
Technical Analysis
Best Analysts Covering MMQ
1 Year
1 Year Success Rate
11/22 ratings generated profit
1 Year Average Return
+31.90%
reiterated a buy rating 26 days ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +31.90% per trade.
---